The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
This French company is addressing vertigo and hearing loss inside the inner ear.
Our company to watch this month is Landos Biopharma, which is aiming for better targeting and better delivery of treatments for GI and other autoimmune diseases.
CytoDyn’s expressed ambitions seem bold but reasonably free of hyperbole. It is only natural to hope for the best possible outcome here, considering the obvious need for new HIV and other immunological therapies.
AmpliPhi Biosciences is pushing bacteriophage-therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.
We check in with the companies we profiled from this section in 2017 to see what has changed … if anything.
This month’s Company To Watch is 10-person Zavante, which is challenging drug resistance with a retooled antibiotic and a broad mechanism of action.
Bridging to commercialization of women’s reproductive health products — starting with a novel contraceptive.
With 24 employees, Paris-based Abivax is in Phase 2 clinical development of its lead drug candidate, which is a potential functional cure for HIV infection. It has also recently spawned an early clinical program in inflammatory bowel disease (IBD).
Madrigal Pharmaceuticals is taking on NASH and other liver diseases by targeting the thyroid hormone beta receptor. The company expects to begin seeing top line Phase 2 trial results in late 2017, with more released in 2018.
By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.
Sage Therapeutics’ CEO Jeff Jonas, M.D., discusses what he means by a “return to the basics of science” at his company.
Summary: Jeff Jonas, M.D., CEO of Sage Therapeutics, discusses some of the challenges of launching a product that could change the paradigm of treating postpartum depression (PPD).
Three manufacturing executives from three different companies (i.e., Allergan, Biogen, and GSK) tackle questions on trends, regions, and the future of biopharmaceutical manufacturing.
BIO 2018 does more than make business meeting history, but facilitates personal connections that can lead toward doing better business.
Miriam Massaad, a biomedical engineering student at Boston University, shares her experiences as a first-time attendee at the 2018 BIO International Convention and Conference in Boston.